Published in Mol Cancer on January 24, 2014
Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis. J Cancer Res Clin Oncol (2015) 0.76
The role of prostate tumor overexpressed 1 in cancer progression. Oncotarget (2016) 0.75
A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma. PLoS One (2017) 0.75
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63
Mechanisms and biological effects of mismatch repair. Annu Rev Genet (1991) 7.86
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA (2006) 7.06
Relating whole-genome expression data with protein-protein interactions. Genome Res (2002) 5.78
Genetic predisposition to colorectal cancer. Nat Rev Cancer (2004) 3.92
The spectrin-based membrane skeleton and micron-scale organization of the plasma membrane. Annu Rev Cell Biol (1993) 2.62
Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA (2006) 2.17
The spectrin repeat: a structural platform for cytoskeletal protein assemblies. FEBS Lett (2002) 2.08
Lynch syndrome genes. Fam Cancer (2005) 1.94
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer (2005) 1.75
Noncanonical mismatch repair as a source of genomic instability in human cells. Mol Cell (2012) 1.63
Recombination proteins mediate meiotic spatial chromosome organization and pairing. Cell (2010) 1.60
Cell shape and interaction defects in alpha-spectrin mutants of Drosophila melanogaster. J Cell Biol (1993) 1.58
Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology (2002) 1.55
MSH4 acts in conjunction with MLH1 during mammalian meiosis. FASEB J (2000) 1.50
Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. J Biol Chem (2006) 1.48
The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res (2001) 1.46
Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci U S A (2005) 1.21
The interacting domains of three MutL heterodimers in man: hMLH1 interacts with 36 homologous amino acid residues within hMLH3, hPMS1 and hPMS2. Nucleic Acids Res (2001) 1.20
Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J Cell Sci (2003) 1.15
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
New insights into functions of erythroid proteins in nonerythroid cells. Curr Opin Hematol (2000) 1.04
Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair. Hum Mutat (2010) 1.02
Identification of the spectrin subunit and domains required for formation of spectrin/adducin/actin complexes. J Biol Chem (1996) 0.98
AlphaII-spectrin is critical for cell adhesion and cell cycle. J Biol Chem (2008) 0.97
Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol (2010) 0.97
Promoters can contribute to the elucidation of protein function. Trends Biotechnol (2003) 0.97
alphaII-Spectrin interacts with five groups of functionally important proteins in the nucleus. Cell Biol Int (2006) 0.95
Immunolocalization of the fodrin, E-cadherin, and beta-catenin adhesion complex in infiltrating ductal carcinoma of the breast-comparison with an in vitro model. J Pathol (1999) 0.93
Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants. Gut (2002) 0.91
Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene (2003) 0.91
Thymosin beta 4 expression and nuclear transport are regulated by hMLH1. Biochem Biophys Res Commun (2007) 0.88
Fodrin as a differentiation marker. Redistributions in colonic neoplasia. Am J Pathol (1989) 0.86
Microsatellite instability and mutations in DNA mismatch repair genes in sporadic colorectal cancers. Dis Colon Rectum (2003) 0.85
The interplay between hMLH1 and hMRE11: role in MMR and the effect of hMLH1 mutations. Biochem Biophys Res Commun (2008) 0.83
Fodrin and actin in the normal, metaplastic, and dysplastic respiratory epithelium and in lung carcinoma. Am J Respir Cell Mol Biol (1994) 0.82
A novel interaction between human DNA polymerase eta and MutLalpha. Biochem Biophys Res Commun (2009) 0.80
Non-erythroid spectrin (fodrin) in cutaneous tumours: diminished in cell membranes, increased in the cytoplasm. Br J Dermatol (1996) 0.78
Cytoskeletal scaffolding proteins interact with Lynch-Syndrome associated mismatch repair protein MLH1. Proteomics (2010) 0.78
A CRM1-dependent nuclear export pathway is involved in the regulation of MutLα subcellular localization. Genes Chromosomes Cancer (2011) 0.78
Altered expression of a structural protein (fodrin) within epithelial proliferative disease of the breast. Am J Pathol (1992) 0.76
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology (2003) 3.09
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol (2007) 2.50
Occult hepatitis C: how convincing are the current data? Hepatology (2009) 2.49
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology (2009) 2.42
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol (2011) 2.40
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) 2.37
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) 2.35
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis (2005) 2.33
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. J Natl Cancer Inst (2013) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol (2013) 2.08
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature (2010) 2.01
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat Chem Biol (2009) 2.00
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology (2010) 1.96
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol (2011) 1.91
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82
Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol (2008) 1.82
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol (2006) 1.77
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology (2009) 1.76
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer (2005) 1.75
Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol (2006) 1.70
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol (2008) 1.69
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol (2013) 1.68
Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology (2013) 1.68
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int (2008) 1.68
Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol (2011) 1.66
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros (2013) 1.66
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
New kinetic models for the hepatitis C virus. Hepatology (2005) 1.63
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int (2012) 1.60
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol (2006) 1.60